Evidence map›Paper›PMID 30919549›Full record

Trial reportEuropean journal of heart failure2019

Clinical factors related to morbidity and mortality in high-risk heart failure patients: the GUIDE-IT predictive model and risk score.

Christopher O'Connor, Mona Fiuzat, Hillary Mulder, Adrian Coles, Tariq Ahmad, Justin A Ezekowitz, Kirkwood F Adams, Ileana L Piña, Kevin J Anstrom, Lawton S Cooper and 5 more

Registry-linked trialOpen access · bronzeAbstract readMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in European journal of heart failure, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01685840 (Guiding Evidence Based Therapy Using Biomarker Intensified Treatment in Heart Failure.), which is not on this map. Cited by 24 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 1 pooled it
4.2field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01685840 naterminatednot on this map

Guiding Evidence Based Therapy Using Biomarker Intensified Treatment in Heart Failure.

TypeinterventionalSponsorDuke UniversityRan2012 to 2016Enrolled894ConditionsHeart FailureArmsUsual Care, Biomarker-guided care NT-proBNP
3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 1 synthesis or guideline pooled it, 48 citations in OpenAlex.

  1. Pooled it
  2. SESC heart failure · 2024
    Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors at 10 institutions in 2 countries.

Christopher O'ConnorInova Heart and Vascular Institute, Fairfax, VA, USA.
Mona FiuzatDuke Clinical Research Institute, Durham, NC, USA.
Hillary MulderDuke Clinical Research Institute, Durham, NC, USA.
Adrian ColesDuke Clinical Research Institute, Durham, NC, USA.
Tariq AhmadSection of Cardiovascular Medicine and Center for Outcomes Research, Yale University School of Medicine New Haven, New Haven, CT, United States.
Justin A EzekowitzCanadian VIGOUR Centre, University of Alberta, Edmonton, Canada; Division of Cardiology, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada.
Kirkwood F AdamsUniversity of North Carolina, Chapel Hill, NC, USA.
Ileana L PiñaAlbert Einstein College of Medicine, Bronx, NY, USA.
Kevin J AnstromDuke Clinical Research Institute, Durham, NC, USA.
Lawton S CooperDivision of Cardiovascular Sciences, National Heart, Lung, and Blood Institute, Bethesda, MD, USA.
Daniel B MarkDuke Clinical Research Institute, Durham, NC, USA.
David J WhellanDepartment of Medicine, Thomas Jefferson University, Philadelphia, PA, USA.
James L JanuzziCardiology Division, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA.
Eric S LeiferDivision of Cardiovascular Sciences, National Heart, Lung, and Blood Institute, Bethesda, MD, USA.
G Michael FelkerDuke Clinical Research Institute, Durham, NC, USA.
Clinical Research Institute · USNational Heart Lung and Blood Institute · USAlbert Einstein College of Medicine · USCanadian VIGOUR Centre · CADuke University · USInova Fairfax Hospital · USMassachusetts General Hospital · USThomas Jefferson University · USUniversity of North Carolina at Chapel Hill · USYale New Haven Health System · US

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
GUIDing Evidence Based Therapy Using Biomarker Intensified Treatment (CCC)R01HL105448 · NHLBI · DUKE UNIVERSITY · PI FELKER, GARY M · 2012 to 2016
$12.8M
NCATS NIH HHS UL1 TR001863NHLBI NIH HHS R01 HL105448
6 · The paper itself

Abstract

backgroundMost heart failure (HF) risk scores have been derived from cohorts of stable HF patients and may not incorporate up to date treatment regimens or deep phenotype characterization that change baseline risk over the short- and long-term follow-up period. We undertook the current analysis of participants in the GUIDE-IT (Guiding Evidence-Based Therapy Using Biomarker Intensified Treatment) trial to address these limitations. METHODS AND

resultsThe GUIDE-IT study randomized 894 high-risk patients with HF and reduced ejection fraction (≤ 40%) to biomarker-guided treatment strategy vs. usual care. We performed risk modelling using Cox proportional hazards models and analysed the relationship between 35 baseline clinical factors and the primary composite endpoint of cardiovascular (CV) death or HF hospitalization, the secondary endpoint of all-cause mortality, and the exploratory endpoint of 90-day HF hospitalization or death. Prognostic relationships for continuous variables were examined and key predictors were identified using a backward variable selection process. Predictive models and risk scores were developed. Over a median follow-up of 15 months, the cumulative number of HF hospitalizations and CV deaths was 328 out of 894 patients (Kaplan-Meier event rate 34.5% at 12 months). Frequency of all-cause deaths was 143 out of 894 patients (Kaplan-Meier event rate 12.2% at 12 months). Outcomes for the primary and secondary endpoints between strategy arms of the study were similar. The most important predictor that was present in all three models was the baseline natriuretic peptide level. Hispanic ethnicity, low sodium and high heart rate were present in two of the three models. Other important predictors included the presence or absence of a device, New York Heart Association class, HF duration, black race, co-morbidities (sleep apnoea, elevated creatinine, ischaemic heart disease), low blood pressure, and a high congestion score.

conclusionRisk models using readily available clinical information are able to accurately predict short- and long-term CV events and may be useful in optimizing care and enriching patients for clinical trials. CLINICAL

trial registrationClinicalTrials.gov ID number NCT01685840.

Indexed as

Disease ManagementAgedBiomarkersCause of DeathComorbidityFemaleHeart FailureHospitalizationHumansMaleMiddle AgedMorbidityNatriuretic Peptide, BrainPrognosisRisk AssessmentRisk FactorsBiomarkersNatriuretic Peptide, BrainNatriuretic peptidesPredictive risk modelRisk stratificationSystolic heart failure

Identifiers

PMID30919549
PMCPMC6830509
OpenAlexW2927013814

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.